Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
69 hedge funds and large institutions have $80.1M invested in Mirati Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 10 closing their positions.
150% more call options, than puts
Call options by funds: $5K | Put options by funds: $2K
5% more capital invested
Capital invested by funds: $76.5M → $80.1M (+$3.63M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
4% less funds holding
Funds holding: 72 → 69 (-3)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$1.63M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$1.46M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.21M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$1.06M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$679K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.7M |
| 2 |
QF
QVT Financial
New York
|
-$2.78M |
| 3 |
Millennium Management
New York
|
-$1.14M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$880K |
| 5 |
Renaissance Technologies
New York
|
-$686K |
MRTX Hedge Fund Activity: Q3 2016 in Review
69 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2016, worth a combined $80.1M — up 4.7% from $76.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of MRTX and 8 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 20 added.
The largest buyer was Broadfin Capital, adding an estimated $1.63M. The largest seller was Fidelity Investments, exiting entirely with an estimated $8.7M sold.
- 69 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2016, down from 72 in Q2 2016.
- Funds reported $80.1M of Mirati Therapeutics, Inc. Common Stock stock for Q3 2016, up 4.7% quarter-over-quarter.
- 8 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2016 and 10 closed out, a net change of -2 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2016 was Broadfin Capital, an estimated $1.63M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2016 was Fidelity Investments, an estimated $8.7M sold.
Based on aggregated 13F filings for Q3 2016.